|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||115.81 - 117.25|
|52 Week Range||102.10 - 149.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||159.17|
The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Nike and Alexion Pharmaceuticals staked out early leads Monday, as strength across global markets helped boost stocks in opening trade.
Alexion Pharmaceuticals, Inc. (ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s Biologics License Application (BLA) for approval of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). The Phase 3 clinical development program of ALXN1210 is the largest-ever Phase 3 program in PNH.
Alnylam Pharmaceuticals’ (ALNY) investigational RNAi therapeutic drug lumasiran is being developed for the treatment of primary hyperoxaluria type 1 (or PH1). Alnylam expects to initiate a Phase 3 trial of the drug in 2018, with its results expected in late 2019.
In August 2018, Jazz Pharmaceuticals (JAZZ) and the University of Texas MD Anderson Cancer Center entered a five-year collaboration agreement to investigate therapies for the treatment of multiple hematologic malignancies such as AML (acute myeloid leukemia) and myelodysplastic syndrome.
On August 7, Jazz Pharmaceuticals (JAZZ) released its second-quarter 2018 financial results. Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.
NEW YORK, Aug. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Washington ...
Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.
Quite often, investors start wondering if this level has made a stock an overpriced one. In fact, a decision to avoid stocks that are trading near their 52-week high levels makes an investor miss out on most of the top gainers. This is because investors fear that the stocks are overvalued and a price crash is impending.
Alnylam Pharmaceuticals’ (ALNY) selling, general, and administrative expenses are expected to rise 73.46% from $45.78 million in the second quarter of 2017 to $79.41 million in the second quarter of 2018, and its research and development expenses are also expected to rise 22.75% from $90.63 million in the second quarter of 2017 to $111.25 million in the second quarter of 2018. Of the 16 analysts covering Alnylam Pharmaceuticals in July, 12 have given the stock “buy” or higher ratings, and three have given it “hold” ratings. In comparison, peers, Amgen (AMGN), Celgene (CELG), Alexion Pharmaceuticals (ALXN), and Bristol-Myers Squibb (BMY) have mean ratings of 2.3, 2.25, 1.74, and 2.55, respectively, and target prices of $203.95, $112.54, $158.89, and $57.56, respectively.
Strong earnings reports from Vertex Wednesday afternoon and Alexion Thursday morning capped off what’s been a string of largely positive news for the companies, whose market values clock in at a not-quite-top-tier $45 billion and $30 billion, respectively.
ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.
Alexion (ALXN) delivered earnings and revenue surprises of 22.49% and 6.55%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The New Haven, Connecticut-based company said it had a loss of $2.05 per share. Earnings, adjusted for one-time gains and costs, were $2.07 per share. The results exceeded Wall Street expectations. The ...
BOSTON-- -- 2Q18 total revenues of $1,045.0 million, a 14 percent increase over 2Q17 and a 16 percent volume increase 2Q18 GAAP diluted EPS of $ per share; non-GAAP diluted EPS of $2.07 per share Filed ALXN1210 submissions for PNH approval in the U.S. and EU and on track to file in Japan in the second half of 2018 AchR Antibody-Positive Generalized Myasthenia Gravis on track to be best launch of any ...
Trade war tensions between the U.S. and China have only intensified over the past few months, causing a growing headache for investors. One day the market gains on optimism of a cease-fire between President Donald Trump and China President Xi Jinping. The next day, one or the other is threatening to slap tariffs on billions of dollars' worth of new goods. The spat began quietly enough in January, when the U.S. imposed tariffs on imports of solar cells and washing machines. As the year has progressed, America has added steel and aluminum imports to the list, then tariffs on another $34 billion in Chinese goods more recently. Numerous threats have been made in between. But the volatility this has sparked in the stock markets is creating buying opportunities in many solid companies that don't have as much to fear should the U.S. actually dive into a full-blown trade war. Particularly attractive are companies that primarily do business within the U.S. Here, the economy is accelerating, consumer spending is strong, inflation is in check and the tax cuts passed in 2017 are heavily benefiting domestic companies. With that in mind, here are six stocks to buy if you're looking for ways to grow your portfolio without worrying about a trade war. SEE ALSO: The Best and Worst Presidents (According to the Stock Market)
Clovis Oncology’s (CLVS) selling, general, and administrative expenses are expected to increase by 12.48% from $36.15 million in the second quarter of 2017 to $40.66 million in the second quarter of 2018. Clovis Oncology is expected to have a net income of -$84.85 million in the second quarter of 2018 compared to a net income of -$175.39 million in the second quarter of 2017. Of the nine analysts covering Clovis Oncology in July, seven have given the stock “buy” or higher ratings, and two have given it “hold” ratings.